Filtered By:
Source: Diabetes Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 48 results found since Jan 2013.
External Validation of the BRAVO Diabetes Model Using the EXSCEL Clinical Trial Data
ConclusionsThis study demonstrates the feasibility of using the BRAVO model in settings where only fully de-identified patient-level data are available.
Source: Diabetes Therapy - July 11, 2023 Category: Endocrinology Source Type: research
Atherosclerotic Cardiovascular Disease in Type 2 Diabetes: A Retrospective, Observational Study of Economic and Clinical Burden in Sweden
ConclusionsASCVD is associated with considerable costs, morbidity and mortality in individuals with T2D. These results support structured assessment of ASCVD risk and broader implementation of guideline-recommended treatments in T2D healthcare.
Source: Diabetes Therapy - June 16, 2023 Category: Endocrinology Source Type: research
Cost –Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand
ConclusionCompared to the SoC treatment, adding liraglutide at the current cost is not cost-effective at the local WTP. People with T2D with ASCVD would have the most potential gain from adding liraglutide treatment compared to other populations.
Source: Diabetes Therapy - January 31, 2023 Category: Endocrinology Source Type: research
Cardiovascular Outcomes Observed with Ticagrelor versus Clopidogrel in Type 2 Diabetes Mellitus Patients with Acute Coronary Syndrome: A Meta-analysis
ConclusionsIn these T2DM patients with ACS, a significantly lower risk of major adverse cardiovascular events including all-cause mortality was observed in the ticagrelor group compared with the clopidogrel group. However, T2DM patients who were assigned to ticagrelor showed a significantly higher minor bleeding risk. Larger clinical trials should be able to confirm these hypotheses.
Source: Diabetes Therapy - December 21, 2022 Category: Endocrinology Source Type: research
Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis
ConclusionLong-term ticagrelor monotherapy after a short course of DAPT use showed better results in patients with T2DM following PCI. Therefore, ticagrelor monotherapy after a short course of DAPT use could be considered an evolution in antiplatelet therapy of this decade for the treatment of patients with T2DM after PCI. However, newer studies with a larger population size and cost-effectiveness are factors that should further be considered.
Source: Diabetes Therapy - December 9, 2022 Category: Endocrinology Source Type: research
Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium–Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan
ConclusionOur results suggest that initiating T2DM treatment with SGLT2i, aimed at managing cardiovascular and renal complications from the early stages of diabetes, can improve the clinical outcome and reduce cost burden of T2DM.
Source: Diabetes Therapy - June 16, 2022 Category: Endocrinology Source Type: research
Manifestation of Heart Failure and Chronic Kidney Disease are Associated with Increased Mortality Risk in Early Stages of Type 2 Diabetes Mellitus: Analysis of a Japanese Real-World Hospital Claims Database
ConclusionsThe high incidence of CKD or HF manifestation can contribute to the augmented mortality risk in patients in the early stages of T2DM compared with patients without T2DM. These findings highlight the importance of early interventions for preventing/treating CKD and HF to improve the prognosis of patients with T2DM.
Source: Diabetes Therapy - January 10, 2022 Category: Endocrinology Source Type: research
Electronic Medical Record Risk Modeling of Cardiovascular Outcomes Among Patients with Type 2 Diabetes
ConclusionsThe Ochsner model overestimated 5-year CHD risk, but had relatively higher calibration than the other models in CHD. Risk equations fitted for local populations improved cardiovascular risk stratification for patients with T2DM. Application of machine learning simplified the models compared to “generalized” risk equations.
Source: Diabetes Therapy - June 18, 2021 Category: Endocrinology Source Type: research
